Anti‐EGFR therapy showed no clear difference in overall survival ‐ first‐line studies compared with placebo or standard of care (moderate certainty).
Anti‐EGFR therapy showed no clear difference in overall survival ‐ recurrent disease studies compared with placebo or standard of care (low certainty).
Anti‐EGFR therapy showed no clear difference in lymphopenia compared with placebo or standard of care (low certainty).
Anti‐EGFR therapy showed no clear difference in neutropenia compared with placebo or standard of care (low certainty).
Anti‐EGFR therapy showed no clear difference in thrombocytopenia compared with placebo or standard of care (low certainty).
Anti‐EGFR therapy showed no clear difference in progression‐free survival ‐ first‐line studies compared with placebo or standard of care (low certainty).
Anti‐EGFR therapy may leads to lower progression‐free survival ‐ recurrent disease studies compared with placebo or standard of care (low certainty).
EGFR tyrosine kinase inhibitor (TKI) showed no clear difference in overall survival compared with observation alone (low certainty).
The review found no eligible studies for this question.
Anti‐EGFR antibody plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (moderate certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 to 4 anaemia compared with chemotherapy alone (low certainty).
It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea compared with chemotherapy alone (very low certainty).
It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea ‐ seribantumab compared with chemotherapy alone (very low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 nausea ± vomiting compared with chemotherapy alone (low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 fatigue compared with chemotherapy alone (low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 hypokalaemia compared with chemotherapy alone (low certainty).
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) changes progression‐free survival compared with observation alone (very low certainty).
The review found no eligible studies for this question.